and are characterized by an overshooting immune reaction in the gastrointestinal tract (GIT). [2-4] This leads to tissue damage and a variety of symptoms [2,5] such as diarrhea as well as extraintestinal symptoms related to malabsorption of nutrients and an increased risk of cancer. [6-8] To date, there is no causal therapy available for inflammatory diseases of the intestine and long-lasting suppression and avoidance of triggers is usually required. [9] IBD is currently treated with immunosuppressive drugs. However, these drugs may not be effective for every patient because of individual pharmacogenetic differences. [10,11] Moreover, these drugs are also known to cause a number of side effects, including hepatic injuries and an increased susceptibility to infections. [12-14] In the case of celiac disease, the patients are required to maintain a lifelong gluten-free diet, which is difficult to achieve in the typical "western diet" as gluten is contained in a variety of food products, and even very small amounts can trigger an autoimmune reaction. [15] Administration of probiotic bacteria has shown efficacy as an adjuvant therapy in ameliorating the symptoms related to IBDs. [16] According to the World Health Organization, probiotics are defined as "live microorganisms, which when administered in adequate amounts, confer a health benefit on the host." [17] These bacteria, which include gram-positive Lactobacilli and Bifidobacteria as well as some Escherichia coli strains, have demonstrated multiple beneficial effects, such as modulation of the host immune system, improvement in the epithelial barrier function, and affecting the balance of the various bacterial strains in the gut. [18] Despite the promising potential of probiotics, they are still not always suitable for use as therapeutic agents because of their ability to proliferate. Especially, in the case of patients who take immunosuppressants for long-term control of IBD, the concomitant use of probiotics is not recommended as it can lead to bacteremia and sepsis. [19] A study reported that Escherichia coli Nissle 1917-a strain commonly used as probiotics-possessed the same genes responsible for pathogenicity as detected in other E. coli strains. [18] Once these silent genes are activated by unknown triggers, they may potentially cause pathogenic effects in patients, thus substantially limiting the safety of the probiotics. In this study, we explored the approach of designing therapeutics based on bacterial membrane vesicles (MVs), There is a lack of efficient therapies to treat increasingly prevalent autoimmune diseases, such as inflammatory bowel disease and celiac disease. Membrane vesicles (MVs) isolated from probiotic bacteria have shown tremendous potential for treating intestinal inflammatory diseases. However, possible dilution effects and rapid elimination in the gastrointestinal tract may impair their application. A cell-free and anti-inflammatory therapeutic system-probiomimetics-based on MVs of probiotic bacteria (Lactobacillus casei and Lactobaci...